Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25796716 | 0.84 | C5AR1 (0.41) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL15636157 | 0.80 | ADORA1 (0.48) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL1885657 | 0.79 | F12 (0.57) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL2074792 | 0.78 | C5AR1 (0.39) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL21183650 | 0.76 | F12 (0.52) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL25796715 | 0.75 | NR1H2 (0.42) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL21725722 | 0.75 | C5AR1 (0.67) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL18852439 | 0.75 | ESR2 (0.39) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL15333088 | 0.74 | C5AR1 (0.46) | F12ADORA1NR1H2C5AR1MAPT | |
| SCHEMBL29504891 | 0.74 | C5AR1 (0.42) | F12ADORA1NR1H2C5AR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | F12 4372/4885ADORA1 534/4885NR1H2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.